ALL MARKETS
FTSE 100
FTSE 250
AIM MARKET

F4TO MYNZ.
30 announcements.
Time Date Ticker Company Announcement
14:02 05-12-2023 F4TO F4TO MYNZ
Mainz Biomed Reports Positive Topline Results from U.S. eAArly DETECT Study Evaluating Novel mRNA Biomarkers
13:02 29-11-2023 F4TO F4TO MYNZ
Mainz Biomed’s Presentation at the 35th Annual Piper Sandler Healthcare Conference to be Made Available via Webcast
13:02 20-11-2023 F4TO F4TO MYNZ
Mainz Biomed to Present at the 35th Annual Piper Sandler Healthcare Conference
13:03 16-11-2023 F4TO F4TO MYNZ
Mainz Biomed Reports Third Quarter 2023 Financial Results and Provides Corporate Update
14:02 15-11-2023 F4TO F4TO MYNZ
Mainz Biomed Announces Closing of $5.0 million Registered Direct Offering
14:01 13-11-2023 F4TO F4TO MYNZ
Mainz Biomed Announces Pricing of $5.0 million Registered Direct Offering
13:02 09-11-2023 F4TO F4TO MYNZ
Mainz Biomed Partners with Liquid Biosciences to Harness the Power of Artificial Intelligence (AI) to Develop Next-generation Colorectal Screening Test
13:02 07-11-2023 F4TO F4TO MYNZ
Mainz Biomed to Showcase ColoAlert® at Leading Global Healthcare Event, MEDICA
12:02 31-10-2023 F4TO F4TO MYNZ
Mainz Biomed Reports Success from Employee Colorectal Cancer Screening Campaign in Partnership with Zöller-Kipper
13:03 26-10-2023 F4TO F4TO MYNZ
Mainz Biomed Appoints Tarrin Khairi-Taraki as VP of Commercial Operations
13:02 18-10-2023 F4TO F4TO MYNZ
Mainz Biomed Presents Groundbreaking Results of ColoFuture Study
13:02 11-10-2023 F4TO F4TO MYNZ
Mainz Biomed to Showcase ColoAlert® at UEG Week 2023 in Copenhagen, Denmark
13:02 05-10-2023 F4TO F4TO MYNZ
Mainz Biomed to Attend the JonesTrading 2023 Healthcare Summit
13:02 04-10-2023 F4TO F4TO MYNZ
Mainz Biomed Announces Live Launch of ColoAlert® with Bioclinica in Romania
13:02 27-09-2023 F4TO F4TO MYNZ
Mainz Biomed to Present Detailed Results of ColoFuture Study at International Conference on Gastroenterology
08:02 20-09-2023 F4TO F4TO MYNZ
Mainz Biomed to Present at the Cantor Fitzgerald Global Healthcare Conference
08:02 13-09-2023 F4TO F4TO MYNZ
Mainz Biomed’s ColoFuture Study, Evaluating its Novel mRNA Biomarkers, Reports Groundbreaking Topline Results Demonstrating Sensitivity for Colorectal Cancer of 94% with Specificity of 97% and Advance
08:02 05-09-2023 F4TO F4TO MYNZ
Mainz Biomed Announces Strategic Partnership with Ärztliches Labor Dr. Buhlmann, Expanding Footprint in German Market
08:02 29-08-2023 F4TO F4TO MYNZ
Mainz Biomed to Present at the H.C. Wainwright Global Investment Conference
08:02 22-08-2023 F4TO F4TO MYNZ
Mainz Biomed Announces Live Launch of ColoAlert® with testDNA Laboratory in Poland
08:02 15-08-2023 F4TO F4TO MYNZ
Mainz Biomed Announces Financial Half Year Results 2023 and Provides Corporate Update
08:02 18-07-2023 F4TO F4TO MYNZ
Mainz Biomed Announces Collaboration with Fugene Genetics in Israel
08:02 29-06-2023 F4TO F4TO MYNZ
Mainz Biomed Secures up to $50M in New Funding
08:03 28-06-2023 F4TO F4TO MYNZ
Mainz Biomed to Attend ESMO World Congress on Gastrointestinal Cancer 2023 in Barcelona, Spain
08:03 20-06-2023 F4TO F4TO MYNZ
Mainz BioMed N.V.: Mainz Biomed Expands into Romania Through Partnership with Bioclinica
08:02 31-05-2023 F4TO F4TO MYNZ
Mainz Biomed Expands Commercial Footprint into Poland
08:02 24-05-2023 F4TO F4TO MYNZ
Mainz Biomed Processes First Patients from Colorectal Cancer Screening Campaign Through its Corporate Health Portal in Partnership with Zöller-Kipper
08:02 16-05-2023 F4TO F4TO MYNZ
Mainz Biomed Announces First Quarter 2023 Financial Results and Provides Corporate Update
08:02 10-05-2023 F4TO F4TO MYNZ
Mainz Biomed Partners with Microba Life Sciences for the Development of PancAlert
08:01 03-05-2023 F4TO F4TO MYNZ
Mainz Biomed Announces Addition of Eurofins GeLaMed to its Growing Network of Lab Partners